The data obtained from the Catalogue of Somatic Mutations in Cancer (COSMIC) and Xena indicate that HRAS, but not NRAS or KRAS, gene mutation frequency was high in urinary tract cancer as compared to other origins (Figure 1A), and HRAS gene expression was significantly greater in bladder urothelial carcinoma as compared to normal bladder samples (Figure 1B), suggesting the importance of HRAS oncogene in tumor progression of urinary tract cancer [8]. This evidence concerns the gene NRAS and bladder transitional cell carcinoma.